Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.

James R WhittleFrançois VaillantElliot SurgenorAntonia N PolicheniGöknur Giner Bianca D CapaldoHuei-Rong ChenHe K LiuJohanna F DekkersNorman SachsHans CleversAndrew FellowesThomas GreenHuiling XuStephen B Fox Marco J Herold Aaron T L LunDaniel H D GrayJane E VisvaderGeoffrey J Lindeman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

This study illustrates the potential for targeting BCL2 in combination with CDK4/6 inhibitors and supports investigation of combination therapy in ER+ breast cancer.

Keyphrases

estrogen receptor
combination therapy
positive breast cancer
cell cycle
cancer therapy
drug delivery
cell proliferation